Novartis Scales Up to Make COVID-19 Vaccine Doses for CureVac
Novartis is upgrading its manufacturing facilities to produce additional doses of CureVac’s messenger RNA-based COVID-19 vaccine, CVnCoV.
Novartis aims to produce up to 50 million doses of the two-dose vaccine by year’s end and to manufacture up to 200 million doses in 2022.
Production at Novartis’ Kundl, Austria, site is expected to start this summer, pending regulatory approval of the vaccine. The European Medicines Agency is currently evaluating CVnCoV under a rolling review and is awaiting data from a late-stage trial in 35,000 participants.